Welcome to our dedicated page for PRO DEX SEC filings (Ticker: PDEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PRO DEX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PRO DEX's regulatory disclosures and financial reporting.
Pro-Dex, Inc. filed its Form 10-K for fiscal 2025 describing operations in medical and scientific devices, including segment sales, balance sheet highlights, financing activity, and governance disclosures. Repairs revenue rose to $18,586 (up from $16,505), CMF sales totaled $9,943 (down ~4%), and thoracic sales increased by $1.3 million to $4.3 million. Operating income improved to $10,689 from $7,173. Investments carried net unrealized gains of $3.3 million at June 30, 2025 versus $1.8 million a year earlier. The company purchased a property for $6.5 million financed with a $5.2 million Property Loan. The revolving credit line was increased to $11.0 million and term loans carry maturities through 2029–2030 with a $3.1 million balloon due at maturity. Share repurchases totaled 130,148 shares at $3.5 million in fiscal 2025. The filing discloses customer concentration (major customer represented ~75% of sales) and notes cybersecurity risk management and standard risk-factor disclosures.
Pro-Dex, Inc. disclosed that its Compensation Committee approved discretionary cash bonuses for its two senior executives. On August 14, 2025, the committee granted a $50,000 bonus to Chief Financial Officer Alisha K. Charlton and a $70,000 bonus to Chief Executive Officer Richard L. Van Kirk. The company states that Mr. Van Kirk’s bonus was based on Pro-Dex’s sales growth and fiscal 2025 financial performance exceeding plan. Both bonuses will be paid in cash in the next bi-weekly pay period, with a pay date of August 21, 2025.